A Crisis Two Decades in the Making

Invasive fungal infections cause an estimated 1.5 million deaths annually—a burden comparable to tuberculosis and exceeding malaria—yet the antifungal drug arsenal has remained stagnant, with no truly new mechanistic class approved in over two decades. This treatment gap is widening as three converging forces accelerate the crisis: expanding immunocompromised patient populations (including those with HIV/AIDS, hematological malignancies, solid organ transplants, chemotherapy, and COVID-19 sequelae), the emergence of intrinsically or acquired multidrug-resistant pathogens, and the structural limitations of the existing three-to-four drug classes.

The major clinical pathogens driving this burden include Candida spp. (particularly C. albicans, C. glabrata, and C. auris), Aspergillus spp. (especially A. fumigatus), Cryptococcus neoformans, and Mucorales. Of these, C. auris has attracted particular attention as a newly emergent, pan-resistant threat. As reported by the CDC and tracked by global surveillance programs, its combination of multidrug resistance and healthcare transmissibility makes it a priority target for the pipeline agents now entering late-stage trials.

The existing antifungal pharmacopoeia rests on three principal mechanisms: azoles (targeting CYP51/ergosterol biosynthesis), echinocandins (inhibiting β-1,3-glucan synthase/FKS), and polyenes such as amphotericin B (binding ergosterol directly). Each class carries significant limitations—azole resistance is now widespread in Aspergillus fumigatus populations in some regions, echinocandin resistance is rising in C. glabrata, and amphotericin B’s nephrotoxicity constrains its use. According to the World Health Organization, fungal pathogens were formally added to WHO’s priority pathogen list in 2022, reflecting the scale of unmet clinical need.

First-in-Class Agents Redefining the Antifungal Arsenal

The most actionable near-term pipeline consists of a cohort of agents at late clinical development stages—several described as being in Phase 2 or Phase 3 trials as of 2021–2022—each exploiting a distinct mechanism to overcome the resistance profiles of existing drug classes. Three agents stand out as genuinely first-in-class by mechanism: fosmanogepix, ibrexafungerp, and olorofim.

Fosmanogepix: Targeting GPI Anchor Biosynthesis

Fosmanogepix is the prodrug of manogepix, the first-in-class inhibitor of the Gwt1 enzyme involved in fungal glycosylphosphatidylinositol (GPI) anchor biosynthesis. GPI anchors are required for cell wall integrity and fungal virulence; disrupting their synthesis is lethal to the fungus. Crucially, fosmanogepix retains activity across a broad spectrum including C. auris, azole-resistant Aspergillus, and rare mold pathogens—organisms against which the current antifungal toolkit is most severely limited.

Ibrexafungerp: The Triterpenoid Glucan Synthase Inhibitor

Ibrexafungerp represents the paradigmatic example of a triterpenoid scaffold acting on the well-validated FKS/β-1,3-glucan synthase target. Unlike classical lipopeptide echinocandins, ibrexafungerp is orally bioavailable—a clinically significant differentiator enabling outpatient treatment and step-down therapy. Its activity against echinocandin-resistant Candida strains harboring FKS hot-spot mutations is specifically noted in the literature, indicating a different binding mode or tolerance profile compared to classical echinocandins. This retained activity against FKS mutants in C. glabrata and C. auris is a key differentiating feature.

“Ibrexafungerp retains activity against FKS hot-spot mutants that confer echinocandin resistance in C. glabrata and C. auris, suggesting a distinct or overlapping binding site with differential sensitivity to resistance mutations.”

Olorofim: DHODH Inhibition and the Orotomide Class

Olorofim is a first-in-class agent in the orotomide drug class, inhibiting fungal dihydroorotate dehydrogenase (DHODH) and therefore blocking pyrimidine biosynthesis in molds. Its particular value lies against cryptic Aspergillus species and other molds with intrinsic triazole resistance—organisms for which no reliable oral therapy previously existed.

Beyond these three first-in-class mechanisms, the pipeline includes rezafungin—a next-generation echinocandin with an extended half-life enabling once-weekly dosing—and novel tetrazole-class azoles including oteseconazole (VT-1161) and VT-1598, engineered for high selectivity toward fungal CYP51 over human CYP51B1 to reduce off-target effects. Opelconazole is an inhaled triazole targeting pulmonary aspergillosis, exploiting a delivery route that maximises local drug concentration while limiting systemic exposure. Encochleated amphotericin B (MAT2203) represents an oral lipid-crystal formulation of the established polyene, designed to reduce the nephrotoxicity that has long constrained amphotericin B’s clinical utility.

Emerging Molecular Targets Beyond the Established Pathways

The most durable long-term pipeline opportunities lie in molecular targets that offer genuine fungal selectivity—either because the target is absent in mammals or because fungal and mammalian orthologs are structurally divergent enough to enable selective inhibition. Several such targets have moved from conceptual identification to lead compound discovery.

Sphingolipid Pathway

Fungal-specific sphingolipids, including inositol phosphorylceramide and glucosylceramide, and their biosynthetic enzymes represent targets with no mammalian ortholog. Research from Stony Brook University has identified several novel compounds that inhibit these enzymes, providing a mechanistic basis for selective antifungal activity without host toxicity.

Calcineurin Signaling

Calcineurin is described as a master regulator of fungal drug tolerance and virulence. FK506 (tacrolimus) inhibits calcineurin in both fungi and human T cells, causing immunosuppression that precludes its use as an antifungal in transplant patients. Research from Duke University Medical Center has focused on redesigning FK506 analogs with selective binding to fungal calcineurin–FKBP12 complexes, exploiting structural differences between human and fungal orthologs to achieve antifungal activity without immunosuppression.

Phosphatidylinositol Transfer Proteins (Sec14-like PITPs)

Fungal Sec14 proteins are structurally divergent from mammalian PITPs, enabling the design of selective inhibitors that disrupt phosphoinositide signaling in pathogenic fungi. Research from Texas A&M University makes the case that this target class offers exquisite fungal selectivity, with no mammalian phosphoinositide signaling disruption expected at therapeutic concentrations.

Two-Component Signaling Systems

Two-component signaling systems are entirely absent in mammals but present in fungi, making them theoretically ideal antifungal targets with a high selectivity ceiling. Research from Rutgers/New Jersey Medical School has proposed these systems as priority antifungal drug targets on this basis.

Thioredoxin Reductase (TRR1)

Virtual screening against Paracoccidioides lutzii TRR1 has identified lead small molecules with fungal-selective activity, according to research from Embrapa Genetic Resources and Biotechnology. This target is particularly relevant for endemic fungal pathogens causing chromoblastomycosis and paracoccidioidomycosis, which are underserved by the current pipeline.

Host Defense Peptides, Drug Repurposing, and Novel Modalities

The preclinical landscape of the invasive fungal infection drug pipeline is dominated by two parallel tracks: host defense peptide (HDP)-derived agents and systematic drug repurposing. Both approaches offer faster routes to candidate identification than de novo medicinal chemistry, and both are producing compounds with activity profiles that complement the clinical-stage small molecules.

Host Defense Peptides and Antimicrobial Peptides

The HDP modality encompasses several structurally distinct sub-categories. Cathelicidin-inspired peptides (“PepBiotics”), developed and patented by Utrecht University, were originally bactericidal against Pseudomonas and S. aureus and have now demonstrated antifungal activity against Aspergillus, Candida, Cryptococcus, and Fusarium. Cysteine-rich antifungal proteins (crAFPs) from filamentous fungi—such as NFAP2 from Neosartorya fischeri—show potent anti-Candida activity and synergy with conventional antifungals. Synthetic antimicrobial peptides (SAMPs) have demonstrated membrane-pore formation, DNA degradation, and apoptosis induction in C. neoformans.

Two polymer-based approaches are particularly notable for their resistance to degradation. Nylon-3 polymers—poly-β-amino acid materials mimicking peptide properties—show broad-spectrum activity across phylogenetically diverse fungi and resistance to proteolytic degradation, addressing a key limitation of natural peptides. β-Peptide polymers (PDAP), inspired by microbial metabolites, have achieved a minimum inhibitory concentration as low as 0.4 µg/mL against C. albicans with no hemolysis and biofilm inhibitory activity, according to research from East China University of Science and Technology.

Drug Repurposing Strategies

Systematic repurposing screens have identified several compelling candidates. A screen of 1,280 FDA-approved off-patent compounds from the Prestwick library against C. auris, conducted by Instituto de Investigación Sanitaria La Fe Valencia, identified 27 inhibitory compounds, with 10 selected for follow-on testing. The anti-rheumatic drug auranofin combined with the anti-protozoal pentamidine has been shown to overcome membrane barrier resistance in C. albicans, including MDR strains, according to research from Sun Yat-sen University. Siramesine, a sigma-2 receptor ligand, was repurposed as an antifungal via in silico drug repurposing followed by in vitro validation against multiple Candida species and molds. HIV protease inhibitors have also demonstrated inhibitory effects on Fonsecaea pedrosoi growth, secreted peptidase activity, and virulence, representing a repurposing opportunity for chromoblastomycosis.

The repurposing track benefits from pre-existing human safety data for established drugs, potentially shortening the path to clinical evaluation. As noted by the NIH in its support of antifungal research programs, the combination of computational screening and in vitro validation is increasingly enabling rapid identification of repurposing candidates for neglected fungal pathogens.

RNA-Based Therapeutics and Nanotechnology

Two further modalities are at earlier conceptual or preclinical stages. RNA-based therapeutics—including antisense and siRNA approaches—have been proposed as an emerging direction for antifungal indications, drawing analogy to mRNA vaccines against SARS-CoV-2; this modality is described as largely unexplored for antifungal indications. Nanotechnology-based drug delivery systems, including liposomes, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, and metallic nanoparticles, are being developed to improve antifungal efficacy and reduce toxicity, with the approved lipid formulations of amphotericin B serving as proof-of-concept.

Combination Strategies and the Synergy Frontier

Combination therapy is a major theme across the invasive fungal infection pipeline literature, addressed from multiple angles: computational synergy databases, small-molecule adjuvants that potentiate existing drugs in resistant strains, and protein-drug combinations exploiting distinct mechanisms simultaneously.

The Antifungal Synergistic Drug Combination Database (ASDCD), developed by the Chinese Academy of Sciences, represents the first systematic computational resource enabling analysis of synergistic interactions across approved and investigational antifungal agents. This infrastructure enables identification of novel combination space that would be impractical to explore empirically.

A particularly striking finding from the University of Manitoba is the identification of 1,4-benzodiazepines as small-molecule adjuvants with no intrinsic antifungal activity that significantly potentiate fluconazole in both azole-susceptible and azole-resistant Candida strains. This adjuvant approach—using a non-antifungal molecule to restore the activity of an established drug against resistant organisms—represents a potentially rapid path to clinical utility, as the safety profiles of benzodiazepines are already well characterised.

“1,4-Benzodiazepines, with no intrinsic antifungal activity, significantly potentiate fluconazole in azole-susceptible and azole-resistant Candida strains—a non-antifungal molecule restoring the activity of an established drug against resistant organisms.”

The NFAP2 cysteine-rich antifungal protein from Neosartorya fischeri has demonstrated synergy with echinocandins in vitro, suggesting protein-drug combinations as another dimension of the combination space. Pyrvinium pamoate combined with posaconazole has shown synergistic effects against C. neoformans in both in vitro and murine in vivo models, according to research from Zhejiang University—though no clinical signals are yet described for this combination.

The global institutional landscape contributing to combination research spans Chinese academic institutions (Chinese Academy of Sciences, Zhejiang University, Sun Yat-sen University), North American centers (University of Manitoba, McMaster University), and European groups. This geographic breadth reflects both the global disease burden and the distributed nature of antifungal innovation—a pattern that, according to OECD analyses of pharmaceutical R&D, is characteristic of therapeutic areas where academic institutions drive early-stage discovery in the absence of concentrated commercial investment.